Urolithiasis pp 267-273 | Cite as

Prophylactic Treatment with Magnesium Hydroxide in Renal Stone Disease

  • G. Johansson
  • U. Backman
  • B. G. Danielson
  • B. Fellström
  • S. Ljunghall
  • B. Wikström


Hammarsten1 demonstrated 50 years ago that magnesium could increase the solubility of calcium oxalate in vitro and proposed that treatment with magnesium could be used to prevent renal calcium stones. Others2–3 have shown that magnesium could decrease the incidence of experimental, calcium stone formation. Using a quantitative technique to evaluate the inhibitors of calcium phosphate precipitation in whole urine, Bisaz et al.4 found that magnesium accounted for approximately 20 per cent of the total inhibitory activity. Experimentally induced, magnesium depletion in the rat has been shown to cause calcification in the proximal tubular cells and the tubular lumen5.


Prophylactic Treatment Calcium Oxalate Renal Stone Stone Disease Serum Magnesium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. Hammarsten, C. R. Lab. Carlsberg 17:1 (1929).Google Scholar
  2. 2.
    T. A. Borden and E. S. Lyon, Invest. Urol. 6:412 (1969).PubMedGoogle Scholar
  3. 3.
    J. F. Desmars and R. Tawashi, Biochim. Biophys. Acta. 313:256 (1973).PubMedCrossRefGoogle Scholar
  4. 4.
    S. Bisaz, R. Felix, W. F. Neuman, and H. Fleisch, Mineral Electrolyte Metab. 1:74 (1978).Google Scholar
  5. 5.
    G. E. Bunce and G. A. King, Exp. Mol. Pathol. 28:322 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    G. Johansson, U. Backman, B. G. Danielson, S. Ljunghall, and B. Wikström, Invest. Urol, (in press).Google Scholar
  7. 7.
    A. Hodgkinson, Clin. Sei. Mol. Med. 46:357 (1974).Google Scholar
  8. 8.
    S. Ljunghall and A. U. Waern, Scand. J. Urol. Nephrol. Suppl. 41:55 (1977).Google Scholar
  9. 9.
    H.-G. Tiselius, L. E. Almgard, L. Larsson, and B. Sörbo, Eur. Urol. 4:241 (1978).PubMedGoogle Scholar
  10. 10.
    B. G. Danielson, G. Johansson, and S. Ljunghall, Scand. J.Urol. Nephrol. Suppl. 51:49 (1979).Google Scholar
  11. 11.
    B. Wikström, U. Backman, B. G. Danielson, B. Fellström, G. Johansson, and S.Ljunghall, in: “Proceedings Fourth International Urolithiasis Research Symposium,” L. H. Smith, B. Finlayson, and W. G. Robertson, ed. Plenum Press, New York (in press).Google Scholar
  12. 12.
    I. Melnick, R. R. Landes, A. A. Hoffman, and J. F. Burch, J. Urol. 105:119 (1971).PubMedGoogle Scholar
  13. 13.
    E. L. Prien and S. F. Gershoff, J. Urol. 112:509 (1974).PubMedGoogle Scholar
  14. 14.
    E. R. Yendt and M. Cohanim, Kid. Int. 13:397 (1978).CrossRefGoogle Scholar
  15. 15.
    U. Backman, B. G. Danielson, G. Johansson, S. Ljunghall, and B. Wikström, Br. J. Urol. 51:175 (1979).PubMedCrossRefGoogle Scholar
  16. 16.
    J. P. Mordes and W. E. C. Wacker, Pharmacol. Reviews 29:273 (1978).Google Scholar
  17. 17.
    S. N. Gershoff and E. L. Prien, Am. J. Clin. Nutr. 20:293 (1967).Google Scholar

Copyright information

© Springer Science+Business Media New York 1981

Authors and Affiliations

  • G. Johansson
    • 1
  • U. Backman
    • 1
  • B. G. Danielson
    • 1
  • B. Fellström
    • 1
  • S. Ljunghall
    • 1
  • B. Wikström
    • 1
  1. 1.Department of Internal MedicineUniversity HospitalUppsalaSweden

Personalised recommendations